Description

Teva Pharmaceutical: Initiation Of Coverage – Its Latest Pivot To Growth: Why AUSTEDO, UZEDY And AJOVY Matter!

Teva Pharmaceutical Industries Limited reported first-quarter 2026 results reflecting ongoing progress in its strategic transformation from a primarily generics-focused company to a diversified biopharmaceutical firm. The company continues to advance its “Pivot to Growth” strategy, which emphasizes four core pillars: growth through innovative products, increased innovation, sustaining generics leadership with an emerging biosimilar portfolio, and focusing the business on high-return areas. First-quarter revenues amounted to approximately $4 billion, representing a 1% decline in local currency but a 7% increase when excluding the divestment of its Japan business and the loss of generic REVLIMID revenues, which was expected. Growth was primarily driven by the innovative portfolio, which grew 41%, notably through products like AUSTEDO (up 41% to $578 million), UZEDY (up 62% to $63 million), and AJOVY (up 35% to $196 million).